STAT+: FDA, CMS look to collaborate with states on health AI
Reported by STAT News · all stories from statnews.com
Editorial digest
The FDA and CMS are exploring joint initiatives with state governments concerning healthcare artificial intelligence. This coordination highlights growing interest in aligning national and local oversight frameworks for clinical technologies.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/30/2026
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Federal health agencies are working quickly to prevent oversight bottlenecks as states prepare clinical artificial intelligence trials.
- Trusted health newsroom10/7/2026
STAT+: Why health AI pilots in Utah may be on a collision course with the FDA
Utah's healthcare artificial intelligence trials may conflict with federal regulatory bodies.
- Trusted health newsroom10/28/2026
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
Epic Systems' expanding market influence is reportedly stifling technological innovation across the healthcare sector.
- Trusted health newsroom10/22/2026
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Federal regulators have completed formal guidelines for software applications paired with medications, drawing positive reactions from pharmaceutical manufacturers.
- Trusted health newsroom10/26/2026
STAT+: HHS relaxes security, transparency rules for health record software used by hospitals
Federal health officials have eased transparency and data protection mandates for hospital electronic record platforms.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.